Login to Your Account



No Mad Pursuit, Analysts Say

Ode on 'Accretion' Urn: Biogen Pays $3.25B for Tysabri Rights

By Randy Osborne
Staff Writer

Wednesday, February 13, 2013
Biogen Idec Inc.'s move to buy all rights from Elan Corp. plc to the blockbuster multiple sclerosis (MS) therapy Tysabri (natalizumab) didn't take long for analysts to applaud, though Wall Street traders spent time digesting the $3.25 billion deal, which includes contingent payments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription